OBJECTIVES

: To perform a Budget impact analysis (BIA) of the introduction of racecadotril in two different presentations: 10 and 30 mg, as adjuvant treatment of diarrhea in children under 5 years, on the National Health System (NHS) of Mexico, considering only hospitalized patients.

METHODS

: The hospitalized patients was estimated from institutional statistics reports in Mexico. For this purpose, 2 scenarios were contemplated, 1) Before the implementation of racecadotril in hospitalized patients, 2) Another scenario was gradually racecadotril was used in hospitalized patients. The time horizon was considered of 5 years, during this time the penetration rate incremented 10% annually until reaching 50%. The only medical direct cost was contemplated to estimate the total mean cost per patient.

RESULTS

: The introduction of racecadotril (10 mg) leads to an annual saving, estimated in $21,025,371 annually, correspond to 0.0301% of the NHS budget. On a similar way for racecadotril (30 mg), an annual saving of $21,129,269 for hospitalized patients, representing 0.0303% of the NHS budget.

CONCLUSIONS

: According to our results, the use of racecadotril in two different presentations, represents a saving on the NHS budget at being indicated to the treatment of diarrhea in hospitalized children under 5 years.